Form 4: Opus Genetics Executive Reports Routine Stock Disposition

Amy Zaremba Rabourn, Head of Financial Quality Assurance at Opus Genetics, reported the disposition of 3,950 common shares for tax withholding purposes.

Summary

• Amy Zaremba Rabourn, an officer and Head of Financial Quality Assurance at Opus Genetics, Inc. (IRD), reported a transaction on January 10, 2026.
• The transaction involved the disposition of 3,950 shares of common stock at a price of $1.93 per share.
• This disposition was not an open market sale but rather shares withheld by the Issuer to satisfy tax withholding obligations related to the vesting and settlement of a restricted stock units award.
• Following this transaction, Amy Zaremba Rabourn beneficially owns 110,018 shares of Opus Genetics common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine tax-related disposition of shares following an RSU vesting event, which is a neutral event for the company's operational or financial outlook.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-open market transaction for tax purposes, not indicative of a discretionary sale by management.
• Employees: The underlying RSU vesting event is a positive for the executive, representing earned compensation.

Key Dates

Keywords

Opus Genetics, IRD, Form 4, Insider Transaction, Stock Disposition, Tax Withholding, Restricted Stock Units, Executive Compensation